Metorthrit

Methotrexate, the active ingredient in Metorthrit, is an antimetabolite (folate antagonist) presented as an injectable solution for intramuscular, intravenous or subcutaneous use. It is employed to modify disease activity in rheumatic conditions and to treat certain cancers and ectopic pregnancy.

GNH USA supplies Metorthrit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression in adult patients. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: induces remission by targeting malignant lymphoblasts. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination chemotherapy. - Ectopic pregnancy: terminates trophoblastic tissue when surgery is not indicated.

Adverse reactions may range from mild to life‑threatening and require monitoring.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Oral mucositis (mouth sores) - Transient elevation of liver enzymes - Mild cytopenias (low white blood cells or platelets) - Alopecia (hair thinning)

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Life‑threatening infection due to bone‑marrow suppression - Acute renal failure - Severe pancytopenia - Anaphylactoid reactions on injection

Methotrexate requires careful assessment and monitoring before and during therapy. - Pregnancy: contraindicated (Category X); avoid in women of childbearing potential unless effective contraception is used. - Renal function: evaluate creatinine clearance; dose adjustment may be needed. - Hepatic function: monitor liver enzymes regularly; avoid in pre‑existing severe liver disease. - Hematologic status: perform baseline and periodic complete blood counts. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - NSAIDs: increase methotrexate toxicity and renal impairment. - Live vaccines: heightened risk of severe infection. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate clearance. - Sulfonamide antibiotics: increase risk of hematologic toxicity. - Alcohol: potentiates hepatotoxic effects.